Abiraterone acetate

From Wikipedia, the free encyclopedia
  (Redirected from Abiraterone)
Jump to: navigation, search
Abiraterone acetate
Systematic (IUPAC) name
Clinical data
Trade names Zytiga
AHFS/Drugs.com monograph
MedlinePlus a611046
Licence data US FDA:link
  • AU: D
  • US: X (Contraindicated)
Legal status
Routes of
Pharmacokinetic data
Protein binding >99%
Metabolism CYP3A4- and SULT2A1-mediated
Biological half-life 12 ± 5 hours
Excretion Faecal (88%), renal (5%)
CAS Number 154229-19-3 N
ATC code L02BX03
PubChem CID 132971
ChemSpider 117349 YesY
UNII G819A456D0 YesY
Chemical data
Formula C24H31NO
Molar mass 349.509 g/mol
 NYesY (what is this?)  (verify)

Abiraterone acetate (INN, USAN, BAN, JAN) (brand names Zytiga, Abiratas, Abretone, Abirapro) is a steroidal antiandrogen, specifically an androgen synthesis inhibitor, used in combination with prednisone in metastatic castration-resistant prostate cancer (formerly hormone-resistant or hormone-refractory prostate cancer) – i.e., prostate cancer not responding to androgen deprivation or treatment with androgen receptor antagonists. It is a prodrug to the active agent abiraterone, and is marketed under the trade name Zytiga. In addition, Intas Pharmaceuticals markets the drug under the trade name Abiratas, Cadila Pharmaceuticals markets the drug as Abretone, and Glenmark Pharmaceuticals as Abirapro.

In April 2011, abiraterone acetate was approved by the U.S. Food and Drug Administration (FDA).[1][2] The FDA press release made reference to a phase III clinical trial in which abiraterone use was associated with a median survival of 14.8 months versus 10.9 months with placebo; the trial was stopped early because of the successful outcome.

Medical uses[edit]

Abiraterone acetate is indicated for use in combination with prednisone as a treatment for metastatic castration-resistant prostate cancer.[3][4][5][6] It has received FDA (28 April 2011), EMA (23 September 2011), MHRA (5 September 2011) and TGA (1 March 2012) approval for this indication.[3][4][5][6] In Australia it is covered by the Pharmaceutical Benefits Scheme when being used to treat castration-resistant prostate cancer and given in combination with prednisone/prednisolone (subject to the conditions that the patient is not currently receiving chemotherapy, is either resistant or intolerant of docetaxel, has a WHO performance status of <2, and his disease has not since become progressive since treatment with PBS-subsidised abiraterone acetate has commenced).[7]

Adverse effects[edit]

Adverse effects by frequency:[3][4][5][6][8]
Very common (>10% frequency):

Common (1-10% frequency):

  • Hypertriglyceridaemia
  • Sepsis
  • Cardiac failure
  • Angina pectoris
  • Arrhythmia
  • Atrial fibrillation
  • Tachycardia
  • Dyspepsia (indigestion)
  • Rash
  • Alanine aminotransferase increased
  • Aspartate aminotransferase increased
  • Fractures
  • Hematuria

Uncommon (0.1-1% frequency):

Rare (<0.1% frequency):


Contraindications include hypersensitivity to abiraterone acetate. It should not be taken by women who are or who may become pregnant. Other cautions include severe baseline hepatic impairment, mineralocorticoid excess, cardiovascular disease, including heart failure and hypertension, uncorrected hypokalaemia, and adrenocorticoid insufficiency.[8]


Abiraterone acetate is a CYP3A4 substrate and hence should not be administered concurrently with strong CYP3A4 inhibitors or inducers.[8] It also inhibits CYP1A2, CYP2C9 and CYP3A4 and likewise should not be taken concurrently with substrates of any of these enzymes that have a narrow therapeutic index.[8]

Mechanism of action[edit]

Abiraterone, the active metabolite of abiraterone acetate, inhibits CYP17A1, which manifests as two enzymes, 17α-hydroxylase (IC50 = 2.5 nM) and 17,20-lyase (IC50 = 15 nm) (six-fold more selective for inhibition of 17α-hydroxylase over 17,20-lyase),[9] that are expressed in testicular, adrenal, and prostatic tumor tissues. CYP17 catalyzes two sequential reactions: (a) the conversion of pregnenolone and progesterone to their 17α-hydroxy derivatives by its 17α-hydroxylase activity, and (b) the subsequent formation of dehydroepiandrosterone (DHEA) and androstenedione, respectively, by its 17,20-lyase activity.[10] DHEA and androstenedione are androgens and precursors of testosterone. Inhibition of CYP17 activity by abiraterone thus decreases circulating levels of androgens such as DHEA, testosterone, and dihydrotestosterone (DHT).

Abiraterone also acts as an antagonist of the androgen receptor (AR) (to some extent) and as an inhibitor of the enzymes 3β-hydroxysteroid dehydrogenase, CYP11B1 (steroid 11β-hydroxylase), and other CYP450s (e.g., CYP1A2, CYP2C9, and CYP3A4).[8][11]

Abiraterone acetate is able to reduce serum testosterone levels to less than 1 ng/dL (i.e., undetectable),[9] and decreases the weights of the prostate gland, seminal vesicles, and testes, in accordance with its antiandrogen action.[12]


After oral administration, abiraterone acetate, the prodrug form present in the commercial preparation, is converted into the active form, abiraterone; this conversion is likely to be esterase-mediated and not CYP-mediated. Administration with food increases absorption of the drug and thus has the potential to result in increased and highly variable exposures; the drug should be consumed on an empty stomach at least one hour before or two hours after food. The drug is highly protein bound (>99%), and is metabolised in the liver by CYP3A4 and SULT2A1 to inactive metabolites. The drug is excreted by feces (~88%) and urine (~5%) with a terminal half life of 12 ± 5 hours.[13]


In the early 1990s, Mike Jarman, Elaine Barrie and Gerry Potter of the Cancer Research UK Centre for Cancer Therapeutics within the Institute of Cancer Research in London set out to develop drug treatments for prostate cancer. Starting from the drug ketoconazole, they developed abiraterone as a more effective variant, filing a patent in 1993 and publishing the first paper describing the drug the following year.[14][15] Rights for commercialisation of the drug were assigned to BTG plc, a UK-based specialist healthcare company. BTG then licensed the product to Cougar Biotechnology which began development of the commercial product.[16] In 2009, Cougar was acquired by Johnson & Johnson which developed and sells the commercial product, and is conducting ongoing clinical trials to expand its clinical uses.[17]

Abiraterone acetate is licensed by the European Medicines Agency.[18] Until May 2012 the National Institute for Health and Clinical Excellence (NICE) did not recommend use of the drug within the NHS on cost-effectiveness grounds. This position was reversed when the manufacturer submitted revised costs.[19] The use is currently limited to men who have already received one docetaxel-containing chemotherapy regimen.[20][21]

Clinical studies[edit]

A phase III trial in subjects previously treated with docetaxel started in 2008.[22] A placebo-controlled randomised phase III clinical trial in patients with castration-refractory prostate cancer who are chemotherapy-naive opened to accrual in April 2009.[23][24]

In September 2010, an independent panel found that the interim results of the phase III clinical trial in previously treated docetaxel patients were so successful that it would have been unethical to keep half the trial participants on placebo, and all patients began receiving the drug.[2] Overall survival was increased by 3.9 months according to this trial (14.8 months versus 10.9 months for placebo). It was approved by the FDA in April 2011.[25]

A double-blind phase III randomised controlled trial investigated the use of abiraterone acetate in men with metastatic castration-resistant prostate cancer with no previous chemotherapy. They randomly assigned 1,088 patients to receive abiraterone acetate (1000 mg) plus prednisone (5 mg twice daily) or placebo plus prednisone. The median radiographic progression-free survival was 16.5 months with abiraterone acetate–prednisone and 8.3 months with prednisone alone (hazard ratio (HR) = 0.53; 95% confidence interval (CI), 0.45 to 0.62; P<0.001). After a median follow-up period of 22.2 months, overall survival was improved with abiraterone acetate–prednisone (median not reached, vs. 27.2 months for prednisone alone; HR = 0.75; 95% CI, 0.61 to 0.93; P=0.01).[26]

See also[edit]


  1. ^ "FDA approves Zytiga for late-stage prostate cancer" (Press release). Food and Drug Administration (FDA). 2011-04-28. 
  2. ^ a b J&J Expands Options For Prostate Cancer, Investor's Business Daily, 24 September 2010
  3. ^ a b c "ZYTIGA (abiraterone acetate) tablet [Janssen Biotech, Inc.]". DailyMed. Janssen Biotech, Inc. September 2013. Retrieved 24 January 2014. 
  4. ^ a b c "Zytiga : EPAR - Product Information" (PDF). European Medicines Agency. Janssen-Cilag International N.V. 29 October 2013. Retrieved 24 January 2014. 
  5. ^ a b c "Zytiga 250 mg tablets - Summary of Product Characteristics". electronic Medicines Compendium. Janssen-Cilag Ltd. 21 January 2014. Retrieved 24 January 2014. 
  6. ^ a b c "ZYTIGA® abiraterone acetate PRODUCT INFORMATION" (PDF). TGA eBusiness Services. JANSSEN-CILAG Pty Ltd. 1 March 2012. Retrieved 24 January 2014. 
  7. ^ "Pharmaceutical Benefits Scheme - ABIRATERONE". Pharmaceutical Benefits Scheme. Retrieved 24 January 2014. 
  8. ^ a b c d e "Zytiga (abiraterone) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 24 January 2014. 
  9. ^ a b Stephen Neidle (30 September 2013). Cancer Drug Design and Discovery. Academic Press. pp. 341–342. ISBN 978-0-12-397228-6. 
  10. ^ Attard G, Belldegrun AS, de Bono JS (December 2005). "Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer". BJU Int. 96 (9): 1241–6. doi:10.1111/j.1464-410X.2005.05821.x. PMID 16287438. 
  11. ^ Yin L, Hu Q (2014). "CYP17 inhibitors--abiraterone, C17,20-lyase inhibitors and multi-targeting agents". Nat Rev Urol 11 (1): 32–42. doi:10.1038/nrurol.2013.274. PMID 24276076. 
  12. ^ Donald J. Tindall; Mohler James (20 April 2009). Androgen Action in Prostate Cancer. Springer Science & Business Media. pp. 748–. ISBN 978-0-387-69179-4. 
  13. ^ "Zytiga prescribing information" (pdf). Janssen Biotech. May 2012. Retrieved 2012-05-19. 
  14. ^ Scowcroft H (2011-09-21). "Where did abiraterone come from?". Cancer Research UK. Retrieved 2011-09-28. 
  15. ^ "A new way to treat prostate cancer: The story of abiraterone". The Institute of Cancer Research. 2012-09-10. Retrieved 2012-11-12. 
  16. ^ "Abiraterone Acetate (CB7630)". Cougar Biotechnology. Archived from the original on 7 September 2008. Retrieved 2008-08-20. 
  17. ^ "Johnson & Johnson Announces Definitive Agreement to Acquire Cougar Biotechnology, Inc." (Press release). Cougar Biotechnology. 2009-05-11. Archived from the original on 29 May 2009. Retrieved 2009-06-03. 
  18. ^ EMA assessment of Zytiga (abiraterone)
  19. ^ "Prostate cancer (metastatic, castration resistant) - abiraterone (following cytoxic therapy): final appraisal determination guidance". NICE guidance. 15 May 2012.
  20. ^ "NICE technology appraisal guidance [TA259]". NICE guidance. June 2012.
  21. ^ "NICE appraisal of earlier treatment with abiraterone for prostate cancer". NICE press release. 14 August 2014.
  22. ^ "NCT00638690". ClinicalTrials.gov. Archived from the original on 21 August 2008. Retrieved 2008-08-22. Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy 
  23. ^ "NCT00887198". ClinicalTrials.gov. Retrieved 2009-12-29. Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer 
  24. ^ "BTG and Ortho Biotech's Prostate Cancer Trial Unblinded". Genetic Engineering & Biotechnology News. 2010-09-10. Retrieved 2011-05-26. 
  25. ^ "FDA Approval for Abiraterone Acetate". 
  26. ^ Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE (December 2012). "Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy". N. Engl. J. Med. 368 (2): 138–48. doi:10.1056/NEJMoa1209096. PMC 3683570. PMID 23228172. 

External links[edit]